# A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Source: https://onco.cc/trials/nct05893888/  
OnCo record `nct05893888` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Cisplatin in head and neck squamous cell carcinoma, run by Privo Technologies, now recruiting.

## Summary

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers is a phase 2/3 interventional study registered as NCT05893888 by Privo Technologies, with 40 participants planned, started 2024-11-07 and due to reach its primary completion in 2026-10. Interventions recorded: PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System) and PRV131 (Cisplatin Intratumoral Injectable).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05893888
- Phase: 2/3
- Setting: A Phase 1/2/3 Multicenter Study Evaluating the PRV Platform of Localized Nanoengineered Therapies for Oral Cavity and Lung Cancers
- Sponsor: Privo Technologies
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05893888: https://clinicaltrials.gov/study/NCT05893888

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct05893888.json